Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.

Grandage VL, Everington T, Linch DC, Khwaja A.

Br J Haematol. 2006 Nov;135(3):303-16. Epub 2006 Sep 4.

PMID:
16956345
2.

Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.

Derenzini E, Younes A.

Expert Opin Investig Drugs. 2013 Jun;22(6):775-85. doi: 10.1517/13543784.2013.775244. Epub 2013 Feb 26. Review.

PMID:
23442043
3.

Profile of pacritinib and its potential in the treatment of hematologic disorders.

Hatzimichael E, Tsolas E, Briasoulis E.

J Blood Med. 2014 Aug 19;5:143-52. doi: 10.2147/JBM.S51253. eCollection 2014. Review.

4.

Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality.

Sellar R, Losman JA.

Hematol Oncol Clin North Am. 2017 Aug;31(4):565-576. doi: 10.1016/j.hoc.2017.04.001. Epub 2017 May 17. Review.

PMID:
28673388
5.

New Therapeutic Strategies in Acute Lymphocytic Leukemia.

Man LM, Morris AL, Keng M.

Curr Hematol Malig Rep. 2017 Jun;12(3):197-206. doi: 10.1007/s11899-017-0380-3. Review.

PMID:
28353016

Supplemental Content

Support Center